Virax Biolabs Group Ltd. Class A (VRAX) Financial Statements
Virax Biolabs Group Ltd. Class A Financial Overview
Virax Biolabs Group Ltd. Class A's market cap is currently $1.63M. The company's EPS TTM is $-24.89; its P/E ratio is -0.05; Virax Biolabs Group Ltd. Class A has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 26 | Mar 25 | Mar 24 | Mar 23 | Sep 22 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 12.42K | $ 6.33K | $ 156.42K | ― | $ 0.00 |
| Gross Profit | $ 7.69K | $ -53.07K | $ 50.59K | ― | $ 0.00 |
| Operating Income | $ -6.40M | $ -6.16M | $ -6.50M | $ -5.73M | $ -1.73M |
| EBITDA | $ -5.43M | $ -5.80M | $ -6.61M | $ -5.44M | $ -750.00 |
| Net Income | $ -5.02M | $ -6.06M | $ -6.73M | $ -5.46M | $ -1.71M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 6.52M | $ 4.23M | $ 3.59M | $ 9.35M | $ 21.76K |
| Total Assets | $ 8.32M | $ 6.43M | $ 5.48M | $ 9.81M | $ 48.71K |
| Total Debt | $ 414.39K | $ 377.00K | $ 224.30K | $ 146.25K | $ 3.76K |
| Net Debt | $ -6.02M | $ -3.85M | $ -3.36M | $ -9.21M | $ -18.00K |
| Total Liabilities | $ 989.83K | $ 964.75K | $ 345.19K | $ 908.40K | $ 1.25M |
| Stockholders' Equity | $ 7.58M | $ 5.70M | $ 5.37M | $ 9.13M | $ -974.58K |
| Cash Flow | |||||
| Free Cash Flow | $ -4.88M | $ -5.17M | $ -7.41M | $ -4.36M | $ -809.07K |
| Operating Cash Flow | $ -4.62M | $ -4.56M | $ -6.25M | $ -4.18M | $ -809.07K |
| Investing Cash Flow | $ -255.83K | $ -603.89K | $ -1.16M | $ -178.40K | $ 0.00 |
| Financing Cash Flow | $ 7.09M | $ 5.81M | $ 1.65M | $ 13.69M | $ 813.21K |
Currency in USD